Core Viewpoint - The announcement details the listing and circulation of restricted shares related to the acquisition of assets by Shanghai Haoyuan Pharmaceutical Co., Ltd, with a total of 4,493,210 shares set to be listed on July 16, 2025 [1][9]. Summary by Sections Listing of Restricted Shares - The company will list 4,493,210 restricted shares, which were issued to specific investors for asset acquisition and fundraising [1][2]. - The shares were registered on December 22, 2022, following approval from the China Securities Regulatory Commission [2]. Changes in Share Capital - Following the issuance of shares, the total share capital of the company increased from 104,078,810 shares to 106,982,272 shares [2]. - The company’s total share capital further increased to 150,217,339 shares after a capital increase of 0.40 shares per existing share was approved [3]. Performance Compensation - The shareholders involved in the asset acquisition, including WANG YUAN and others, are required to fulfill performance compensation obligations due to unmet performance commitments by the acquired company [6][8]. - A total of 47,725 shares were repurchased and canceled as part of the performance compensation process, reducing the total share capital to 211,561,848 shares [7]. Compliance and Verification - The independent financial advisor confirmed that the shareholders have adhered to their commitments regarding the lock-up period and performance compensation [8][9]. - The listing of the restricted shares complies with relevant regulations and the company’s disclosure is deemed accurate and complete [9]. Details of the Restricted Shares - The total number of restricted shares being listed represents 2.12% of the company's total share capital as of July 7, 2025 [10].

Group 1: New Zealand and Australia Economic Outlook - Westpac Bank expects the Reserve Bank of New Zealand to keep the official cash rate unchanged in July, adopting a wait-and-see approach for future rate adjustments [1] - The Reserve Bank of New Zealand may allow the market to interpret potential rate changes and will decide based on economic data released before the August monetary policy statement [1] - The Reserve Bank of New Zealand might indicate that economic activity in Q1 2025 could exceed expectations, although subsequent indicators show a slowdown in economic momentum [1] - The Reserve Bank of Australia did not cut rates in July as widely anticipated, but future rate cuts remain a possibility, contingent on upcoming inflation data [2] - The Reserve Bank of Australia stated that inflation risks have become more balanced, suggesting that while there is no immediate pressure to cut rates, it may be delayed rather than canceled [2] Group 2: Japan's Economic Challenges - Mizuho Securities analysts suggest that the Bank of Japan should maintain its current policy amid external uncertainties, particularly regarding U.S. tariffs [3] - The potential for a 25% tariff on Japanese imports by the U.S. starting August 1 adds uncertainty and could negatively impact Japan's exports and overall economic performance [3] - Mitsubishi UFJ Securities economists believe that U.S. tariffs will challenge Japan's economy, especially in exports and capital investment, prompting the government to consider broader economic stimulus measures [3] - Japan's central bank plans to slow the pace of its bond purchase reduction starting April 2026, considering market stability and participant feedback [3] Group 3: Singapore's Economic Performance - DBS Group economists indicate that Singapore's economy may avoid technical recession in Q2 2025 due to early shipments by export companies, which temporarily supported actual export growth [4] - While short-term export data appears strong due to early deliveries, long-term challenges loom for Singapore's export sectors, particularly electronics and biopharmaceutical manufacturing, due to potential U.S. tariff measures [4]

Core Viewpoint - Kangpeng Technology is strategically expanding its presence in the pharmaceutical sector, particularly focusing on peptide business as a key development direction [1][2]. Group 1: Strategic Focus - In March 2025, Kangpeng Technology approved a project to enhance the manufacturing capacity of medical peptides, planning to invest 75 million yuan, marking a significant shift from traditional fine chemicals to innovative pharmaceutical raw materials [2]. - The company has a history of collaboration with pharmaceutical innovators, leveraging its technical advantages in the early stages of raw material drug development [2]. - Kangpeng Technology has accumulated 115 patents, including 66 invention patents, with core technologies centered around fluorination and carbon-carbon coupling, providing a solid foundation for peptide business development [2]. Group 2: R&D Breakthrough - In 2024, despite facing short-term pressure from intensified competition and weak market demand, Kangpeng Technology's R&D investment reached 85.39 million yuan, accounting for 12.65% of revenue, reflecting a commitment to a technology-driven strategy [3]. - The company is optimizing its new materials segment through dual strategies of process optimization and market expansion, with a complete industrial chain expected from the liquid crystal project in Quzhou [3]. - Kangpeng Technology has established stable partnerships with major pharmaceutical companies, including Merck, Eli Lilly, and Bayer, which positions it well for growth in the peptide raw material business [3]. Group 3: Compliance Operations - Kangpeng Technology emphasizes compliance and risk management, as evidenced by a recent legal dispute resolution that reduced the principal amount owed by 1.34 million yuan [5]. - The company has demonstrated transparency in information disclosure and has implemented a restricted stock incentive plan for 160 core personnel, signaling a commitment to long-term growth [6]. Group 4: Future Outlook - The company's focus on peptide business aligns with the growing demand for innovative drug raw materials, supported by government policies aimed at enhancing the drug pricing mechanism and promoting innovative drugs [7]. - With the advancement of the medical peptide manufacturing capacity enhancement project and the conversion of R&D investments into technological barriers, Kangpeng Technology is expected to achieve breakthroughs in the peptide sector, enriching its product pipeline in the pharmaceutical field [7].

Core Viewpoint - The company, New Mile Health Technology Group Co., Ltd., has achieved significant growth in revenue and profit in 2024, driven by strategic restructuring, resource integration, and technological innovation in the healthcare sector [1][3]. Group 1: Financial Performance - In 2024, the company reported a revenue of 3.799 billion yuan and a net profit attributable to shareholders of 115 million yuan, marking a substantial year-on-year increase of 296.13% [1]. Group 2: Healthcare Services Development - The company is addressing the uneven distribution of medical resources in China by expanding its healthcare services through strategic restructuring and scale expansion, focusing on regional medical needs [3]. - Key hospitals under the company, such as Siyang Hospital and Lankao First Hospital, are enhancing their specialized capabilities and optimizing their discipline layout to improve patient care [3]. - The company has successfully created a virtuous cycle of "scale expansion - quality improvement - efficiency growth" by enhancing operational efficiency and cost control, leading to increased market share and patient satisfaction [3]. Group 3: Pharmaceutical Manufacturing - With over 20 years in pharmaceutical manufacturing, the company has established a competitive advantage in the traditional Chinese medicine sector, centered around its core product, "Duyiwei Capsule" [3]. - The "Duyiwei Capsule" has been recognized for its unique efficacy, high safety, and low treatment costs, being included in the Chinese Pharmacopoeia and various national medical insurance directories [3]. Group 4: Marketing and Brand Development - The company has developed a dual-driven marketing model of "distribution + specialized academic promotion," investing in academic promotion for nearly a decade to build a stable sales team [4]. - The "Duyiwei" trademark was awarded "China Famous Trademark" in 2024, further solidifying its market position [4]. Group 5: Industry Trends and Future Outlook - The healthcare industry in China is experiencing favorable conditions due to an aging population and increasing chronic disease prevalence, with over 260 million chronic disease patients [4]. - The company plans to continue focusing on its dual main businesses of "healthcare + pharmaceuticals," enhancing regional medical center construction and increasing investment in innovative drug research and development [4].

其 他 报 告 2025年07月08日 晨会纪要 | 国内市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 上证综合指数 | 3473 | 0.02 | 1.40 | | 深证成份指数 | 10436 | -0.70 | 1.25 | | 沪深300指数 | 3965 | -0.43 | 1.54 | | 创业板指数 | 2130 | -1.21 | 1.50 | | 上证国债指数 | 226 | 0.06 | 0.16 | | 上证基金指数 | 6939 | -0.05 | 0.16 | | | | 资料来源:同花顺iFinD | | | 海外市场 | | 涨跌幅（%） | | | --- | --- | --- | --- | | 指数 | 收盘 | 1日 | 上周 | | 中国香港恒生指数 | 23888 | -0.12 | -1.52 | | 中国香港国企指数 | 8609 | -0.01 | -1.75 | | 中国台湾加权指数 | 22429 | -0.53 | -0.14 | | 道琼斯指数 | 44829 | ...

Key Points - The U.S. President Trump announced new tariffs on imports from 14 countries, including a 25% tariff on goods from Japan and South Korea, and tariffs ranging from 25% to 40% on Malaysia, South Africa, Indonesia, Myanmar, and Thailand, effective August 1 [9] - The Federal Reserve Chairman candidate, Waller, suggested that the Fed should lower interest rates further, while a Fed report warned of potential zero interest rate risks due to uncertain economic outlook [11] - OPEC+ is expected to approve a significant production increase of approximately 550,000 barrels per day in September [11] Market Overview - WTI crude oil rose by 2.11% to $67.01 per barrel, while Brent crude oil increased by 1.65% to $69.02 per barrel, driven by strong demand despite concerns over OPEC+ production increases and U.S. tariffs [3] - The U.S. dollar index increased by 0.58% to 97.51, while the 10-year Treasury yield closed at 4.385% [6] - The Dow Jones Industrial Average fell by 0.94%, the S&P 500 dropped by 0.79%, and the Nasdaq Composite decreased by 0.92%, with notable declines in stocks like Tesla and Apple [3] Stock Market Performance - Hong Kong's Hang Seng Index closed down 0.12%, while the Hang Seng Tech Index rose by 0.25% [4] - In the A-share market, the Shanghai Composite Index increased by 0.02%, while the Shenzhen Component and ChiNext Index fell by 0.7% and 1.21%, respectively [5] - The cryptocurrency sector saw significant gains, with some stocks rising over 10%, while sectors like biomedicine and dairy products faced declines [4][5]

Core Viewpoint - A total of 2,931 A-share listed companies have completed their 2024 annual profit distribution plans as of July 7, with several companies planning significant dividends for 2025 mid-term distributions [1][2][4]. Group 1: 2024 Annual Profit Distribution - Companies such as Yinbang Co., Zancore Co., and Boji Medicine have announced their 2024 annual profit distribution plans, with cash dividends ranging from 0.1 yuan to 0.17 yuan per share [1][2][3]. - For instance, Yinbang Co. plans to distribute 0.1 yuan per 10 shares, while Zancore Co. will distribute 0.17 yuan per share, and Boji Medicine will distribute 0.12 yuan per 10 shares [2][3]. - Notably, Laofengxiang plans to distribute a cash dividend of 1.72 yuan per A-share and 0.240133 USD per B-share [3]. Group 2: Upcoming Significant Dividends - Companies like Kingsoft Office, Sulian Co., Hualan Biological Engineering, Laofengxiang, Changhong Huayi, and Guangdong Expressway A are expected to announce substantial dividend distributions [2][4]. - Sulian Co. plans to distribute 8 yuan per 10 shares and additionally issue 3 bonus shares for every 10 shares held [3]. Group 3: Mid-term Profit Distribution Plans - Over 320 A-share listed companies have announced plans for mid-term profit distributions for 2025, indicating a trend towards more frequent dividend payments [4][5]. - The increase in mid-term dividends is seen as a signal of financial stability, governance transparency, and valuation support for companies [5][6]. Group 4: Investor Insights - Analysts suggest that companies increasing dividend frequency and focusing on mid-term distributions can enhance their growth, return, and certainty values [6]. - Investors are advised to consider historical dividend records, cash flow adequacy, and industry characteristics when selecting potential mid-term dividend stocks [6].

Overview - Hainan Haiyao Co., Ltd. has approved a financial assistance agreement with its controlling shareholder, Xinxing Jihua Pharmaceutical Holdings Co., Ltd., for a maximum amount of RMB 500 million, with a borrowing period of three years [1][2]. Financial Assistance Details - The financial assistance will primarily be used for Hainan Haiyao's main business and to supplement working capital [1]. - The annual interest rate for the financial assistance is set at 5% [4]. Related Party Transaction - The transaction constitutes a related party transaction and does not qualify as a major asset restructuring under relevant regulations [2]. - The independent directors have reviewed and approved the transaction, confirming it does not harm the interests of the company or its shareholders, particularly minority shareholders [5]. Company and Shareholder Information - Xinxing Jihua Pharmaceutical Holdings Co., Ltd. was established on March 13, 2018, with a registered capital of RMB 1.5 billion and total assets of RMB 7.655 billion as of April 30, 2025 [2][3]. - The company has already engaged in various related party transactions amounting to RMB 1.35 billion since the beginning of the year [5]. Impact on Company - The financial assistance is expected to optimize the company's debt structure and enhance liquidity, contributing to stable business operations without significant adverse effects on financial status or operational results [4][5].

7月7日，片仔癀连续8个交易日下跌，区间累计跌幅-2.33%。漳州片仔癀药业股份有限公司是以医药制 造为主业的中华老字号企业,由成立于1956年的漳州制药厂在1999年改制创立,于2003年在上交所上市,现 股本6.03亿。 易方达沪深300医药ETF基金经理为余海燕。 财报显示，易方达基金旗下易方达沪深300医药ETF为片仔癀前十大股东，今年一季度减持。今年以来 收益率1.83%，同类排名2076(总3422)。 | 阶段涨幅 | 季度涨幅 年度涨幅 | | | | | | --- | --- | --- | --- | --- | --- | | | 近1周 | 近1月 | 近3月 | 近6月 | 今年来 | | 阶段涨幅 | -0.35% | -1.71% | 6.69% | 6.60% | 1.83% | | 同类平均6 | 1.05% | 3.38% | 3.45% | 10.12% | 5.48% | | 沪深300 | 0.74% | 2.35% | 10.47% | 4.45% | 0.77% | | 跟踪标的� | -0.42% | -1.92% | 5.85% | 5.85% | 1.13 ...

Report Industry Investment Rating No relevant content provided. Core View of the Report - Appropriate realization and waiting for layout opportunities. Currently, the convertible bond market is facing supply - demand contradictions and high valuations. In the context of potential increased volatility in the equity market, convertible bonds may face valuation adjustment pressure. Short - term investment should focus on large - cap debt - biased varieties, avoid bonds with overly high downward - revision expectations, realize profits appropriately, maintain a flexible position, and wait for the next layout opportunity [2][45]. Summary According to the Directory 1. Appropriate Realization, Waiting for Layout Opportunities - **Market Performance in Q2**: The equity market showed a deep "V" trend in Q2. The convertible bond index rose 3.4%, outperforming the Shanghai Composite Index. The low - price index rose 2.7%, and the equal - weighted index rose over 4% [12]. - **Supply - demand Analysis**: In Q2, convertible bond supply accelerated, with 11 new issues and a scale of 8 billion yuan. However, due to maturities and forced redemptions, the total scale decreased by over 55 billion yuan compared to Q1. The short - term supply supplement is limited. On the demand side, it first decreased and then increased. In June, there was a large - scale capital inflow [13][21]. - **Valuation Analysis**: The valuation of balanced convertible bonds rose significantly at the end of June, breaking through the annual high. The valuation of debt - biased convertible bonds reached a historical high, while the valuation of equity - biased convertible bonds remained at a low level [39][40]. 2. Market Review 2.1 Equity Market: Index Continued to Rise Strongly - **Index Performance**: Last week, the Shanghai Composite Index and the ChiNext Index rose 1.4% and 1.5% respectively. The market trading volume rebounded, and the theme hotspots rotated actively [47]. - **Style and Sector Performance**: Industries such as steel and building materials led the rise, while the banking sector reached a new high for the year. Some sectors such as computer and non - bank finance declined [47]. - **Valuation**: The PE (TTM) of all A - shares was 15.76X, and the PE (TTM) of the ChiNext was 36.38X, both showing an upward trend [48]. 2.2 Convertible Bond Market: Valuation Continued to Rise - **Index and Trading Volume**: The CSI Convertible Bond Index closed at 447.46, rising 1.21%. The average daily trading volume was 64.766 billion yuan, a 11.85% increase from the previous period [54]. - **Individual Bond Performance**: Dianhua, Saili, and Anke led the gains, while Jinji, Sanyang, and Jingduan led the losses [54]. - **Valuation**: The conversion premium rate of convertible bonds with a parity of 90 - 110 was 26.42%, and the average YTM of convertible bonds with a parity below 80 was - 0.27%, indicating a significant increase in valuation [56]. 3. Convertible Bond Investment Strategy 3.1 Stock Market - In the short term, the external uncertainty has increased significantly, and the index volatility may intensify. The broad - based index will be in a volatile state, and investors can focus on sectors such as innovative drugs, self - controllability, AI +, and solid - state batteries, as well as industries with improved prosperity [3]. 3.2 Convertible Bonds - The overall view is neutral and cautious, preferring structural individual bond opportunities. Specific areas to focus on include TMT, robotics, low - altitude areas, innovative drugs, debt - resolution directions, price - rising cyclical sectors, bottom - position bonds, and newly - listed bonds [4]. 3.3 Primary Market Tracking - Last week, 2 new convertible bonds were issued, 1 convertible bond was approved by the shareholders' meeting, and 1 convertible bond issuance was accepted by the exchange [5][68].